Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1)

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 4

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

355

HTML

2294

Figures (1-2)

470

Tables (1-2)

517

Sum=3636

Jan 28, 2005 (publication date) through Oct 26, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Jan 28, 2005; 11(4): 580-583
Published online Jan 28, 2005. doi: 10.3748/wjg.v11.i4.580

Table 1 Demographics of patients.

Parameters	*Non-responders (n =* 27)**
Age (yr)	45.2
Gender-male (%)	14 (50%)
Pretreatment HCV RNA (copies/mL)	2195150±1575560
Pretreatment ALT (IU/mL)	142
HCV genotype 1b (%)	28 (100)

Table 2 Histological activity index (HAI) and fibrosis stage in all patients.

Citation: Oguz D, Cicek B, Filik L, Odemis B, Kilic M, Altintas E, Zengin N, Altiparmak E. Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1). World J Gastroenterol 2005; 11(4): 580-583
URL: https://www.wjgnet.com/1007-9327/full/v11/i4/580.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i4.580